FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Proven in Trials, Working in Practice

FORXIGA® is indicated in adults with type 2 diabetes mellitus to improve glycaemic control.1

FORXIGA® has now been prescribed to over 1.3 million patients worldwide2

Introducing FORXIGA®

Forxiga marketing promotion
Forxiga marketing promotion

FORXIGA® was the first sodium-glucose cotransporter 2 inhibitor (SGLT2i). It removes glucose, and its associated calories, via the kidney.1

*Forxiga is not indicated for weight loss. Weight loss was a secondary endpoint in clinical trials. 

Prescribed in over 100,000 patients in the UK
Prescribed in over 100,000 patients in the UK

IQVIA, RxA, Units, September 2017, assumes 1 pack equals 1 patient
*FORXIGA® is not indicated for weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials.1
In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg.1 FORXIGA® is not recommended for use in patients with estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2.1 The use of FORXIGA® with pioglitazone is not recommended.1